Scholar Rock Resubmits BLA for Apitegromab, Sets Late September PDUFA Date

summarizeSummary

Scholar Rock has resubmitted its BLA for lead SMA drug apitegromab to the FDA, with a PDUFA action date expected in late September 2026, resolving a prior regulatory delay.

check_boxKey Events · Product Development and Regulatory · SRRK

• BLA Resubmission for Apitegromab

  Scholar Rock announced the resubmission of its Biologics License Application (BLA) to the FDA for apitegromab, its lead drug for spinal muscular atrophy (SMA).

• PDUFA Date Set for Late September 2026

  The company anticipates FDA acceptance within 30 days and a review period of up to six months, with a Prescription Drug User Fee Act (PDUFA) action date expected in late September 2026.

• Addresses Prior Regulatory Delay

  This resubmission directly addresses the Complete Response Letter (CRL) received in September 2025, which was related to manufacturing observations at a third-party facility, not specific to apitegromab.

• Strengthened Supply Chain

  The resubmission includes both the original Catalent Indiana facility and a second U.S.-based fill-finish facility, in alignment with FDA guidance, to enhance supply chain robustness.

auto_awesomeAnalysis · SRRK · Life Sciences

This filing announces a critical step forward for Scholar Rock's lead drug, apitegromab, by resubmitting its Biologics License Application (BLA) to the FDA. This directly addresses the Complete Response Letter (CRL) received in September 2025, which had delayed commercialization. The company has aligned with the FDA to resubmit prior to reinspection of the Catalent Indiana facility and has included a second fill-finish facility to strengthen the supply chain. The anticipated PDUFA action date in late September 2026 provides a clear timeline for potential approval of this first-in-class muscle-targeted therapy for spinal muscular atrophy (SMA). This development significantly de-risks the regulatory pathway and is a major positive catalyst for the company, especially given the previous financial baseline of widened net loss and increased cash burn.